You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search


( ge-FI-tye-nib )
Exceptional Access Program
  • gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Other Name(s): Iressa®
Appearance: tablet

You might also be interested in